To evaluate the efficacy of ixekizumab combined with tirzepatide in achieving skin clearance and weight loss in patients with moderate-to-severe plaque psoriasis and obesity.
Approach:
Key Findings:
27% of patients receiving ixekizumab plus tirzepatide achieved both complete skin clearance and at least 10% weight loss at 36 weeks.
6% of patients receiving ixekizumab alone achieved the same outcomes.
41% of patients in the combination arm achieved Psoriasis Area and Severity Index 100 compared to 29% in the monotherapy arm.
Interpretation:
The combination therapy demonstrated superior efficacy in achieving both skin clearance and weight loss compared to ixekizumab monotherapy in patients with psoriasis and obesity.
Limitations:
The study population had a high mean BMI (>39 kg/m²) and significant disease burden, which may limit generalizability.
Adverse events were reported, though they were generally mild to moderate.
Conclusion:
Concomitant treatment with ixekizumab and tirzepatide is a promising approach for managing psoriasis in patients with obesity, showing significant improvements in skin clearance and weight loss.
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
